Novel Therapies in Osteoarthritis

PRP & Cell-Based Therapies - Blood & Marrow Magic

• Platelet-Rich Plasma (PRP): Autologous concentrated platelets (3-8x baseline).
  • Preparation: Centrifugation.
  • Types: Leukocyte-Rich (LR-PRP), Leukocyte-Poor (LP-PRP).
  • Activation: Thrombin/$CaCl_2$ releases growth factors ($PDGF$, $TGF-\eta$).
  • MOA: Modulates inflammation, promotes healing.
• Mesenchymal Stem/Stromal Cells (MSCs):
  • Sources: Bone Marrow (BMAC - typical $1-5 \times 10^6$ cells/mL), Adipose (AD-MSCs), Umbilical Cord (UC-MSCs). 📌 B.A.U. for sources!
  • MOA: Primarily paracrine signaling (trophic factors); less by differentiation.

  ⭐ MSCs primarily exert their therapeutic effects in osteoarthritis via paracrine signaling (secretion of trophic factors) rather than direct differentiation into chondrocytes.

• Autologous Conditioned Serum (ACS/Orthokine):
  • Preparation: Blood incubated with glass beads, serum collected.
  • MOA: ↑$IL-1Ra$, blocks $IL-1$ inflammatory effects.


Growth Factors & Cytokines - Signal Saviors

• Sprifermin (rhFGF-18)
  • MOA: Recombinant human Fibroblast Growth Factor 18; ↑ chondrocyte proliferation & extracellular matrix (ECM) production.
  • Trials: Showed ↑ cartilage thickness (e.g., FORWARD trial, 100 µg dose). Intra-articular.
• IL-1 Antagonists
  • Anakinra: Recombinant IL-1 receptor antagonist (IL-1Ra). Blocks IL-1.
    • Efficacy: Modest, short-term pain relief. Intra-articular.
  • Diacerein: Oral. Inhibits IL-1β synthesis & activity.
    • Efficacy: Symptomatic relief; potential slow-acting disease-modifying (DMOAD) effect.
• TNF-α Inhibitors (e.g., Infliximab, Etanercept)
  • MOA: Block Tumor Necrosis Factor-alpha.
  • Role in OA: Limited efficacy in primary OA. May benefit inflammatory OA phenotypes. Not routine.
• Other Growth Factors (Investigational)
  • BMP-7 (Bone Morphogenetic Protein-7): Promotes chondrogenesis, cartilage repair.
  • TGF-β (Transforming Growth Factor-beta): Complex role; anabolic at low doses, potentially fibrotic/catabolic at high doses.

⭐ Sprifermin (recombinant human Fibroblast Growth Factor 18) has shown evidence of increased cartilage thickness in some clinical trials for knee osteoarthritis.

Gene Therapy & RNAi - Cartilage Coders

Altering chondrocyte gene expression to combat osteoarthritis (OA).

• Gene Therapy: Delivers therapeutic genes into joint cells.

  • Vectors:
    • Viral: AAV, Lentivirus (efficient delivery).
    • Non-viral: Plasmids (safer, lower efficiency).
  • Target Genes:
    • Anti-catabolic: $IL-1Ra$, TIMPs (↓cartilage degradation).
    • Anabolic: $SOX9$, $TGF-β$, $IGF-1$ (↑matrix synthesis).
  • Delivery: Intra-articular injection; ex vivo (cells modified, then implanted).

  ⭐ Adeno-associated virus (AAV) vectors are favored for in vivo gene therapy in osteoarthritis due to their safety profile and ability to transduce chondrocytes effectively.

• RNA Interference (RNAi): Silences detrimental genes using:

  • Molecules: siRNA (small interfering), shRNA (short hairpin).
  • Targets: $MMPs$, $ADAMTS$ (key cartilage-degrading enzymes).

DMOADs & Pathway Inhibitors - Degeneration Decelerators

Disease-Modifying Osteoarthritis Drugs (DMOADs) aim to slow structural progression in OA. Key pathway inhibitors:

• Wnt Pathway Inhibitors:
  • Lorecivivint (SM04690): Intra-articular.

    ⭐ Lorecivivint (SM04690) is an intra-articular small molecule inhibitor of the Wnt pathway that has shown potential as a DMOAD by promoting chondrogenesis.

  • MOA: Modulates Wnt, ↑chondrogenesis, ↓degradation. Trials ongoing.
• ADAMTS-5 Inhibitors:
  • MOA: Block aggrecan degradation in cartilage.
  • Challenges: Specificity, delivery, efficacy.
• Cathepsin K Inhibitors:
  • MOA: Reduce collagen degradation, bone resorption.
  • Status: Mixed OA trial results; some halted.
• Senolytics:
  • MOA: Eliminate senescent cells, ↓inflammation & degradation.
• PCSK9 Inhibitors:
  • Emerging role in OA; research ongoing.

​

• PRP & MSCs: Key biologics for OA, using autologous factors/cells; efficacy varies.
• Tanezumab (anti-NGF mAb): Potent pain relief but risk of Rapidly Progressive OA (RPOA).
• Sprifermin (rhFGF-18): Growth factor aiming to ↑cartilage thickness, potential DMOAD.
• Gene Therapy: Intra-articular delivery of anti-inflammatory (e.g., IL-1Ra) or chondrogenic factors.
• Lorecivivint (Wnt inhibitor): Small molecule with DMOAD potential; targets cartilage degradation.
• Intra-articular delivery is preferred for most novel therapies to enhance local effects.